ProSomnus Sleep Technologies is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea, a common and serious medical disease. Obstructive Sleep Apnea is associated with comorbidities that include heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. In August, the company announced that it had been included on the prestigious Inc. 5000 list of fastest growing private companies in the U.S. for 2025. This is the fourth year that ProSomnus has earned a spot on the Inc. 5000 list. ProSomnus ranked number 79 in Manufacturing and number 102 in the San Francisco Bay Area on the list. “Persistent and robust organic demand for ProSomnus’s sleep apnea devices, as opposed to price increases or acquisitions, was the exclusive driver of growth,” according to company officials.

The Inc. 5000 list offers a data-driven snapshot of the most successful businesses in the United States. Executives say this recognition underscores ProSomnus’s commitment to advancing patient care through precision-custom intraoral medical devices that closely track the anatomy and treatment plan for each individual patient. ProSomnus devices have demonstrated safe, effective, and patient preferred outcomes in more than a dozen clinical trials.

“ProSomnus is honored to be recognized by Inc. for the fourth year,” says Len Liptak, Chief Executive Officer of ProSomnus Sleep Technologies. “This achievement mirrors the dedication of ProSomnus team members, inputs from leading healthcare providers, and the burgeoning preference for personalized, non-CPAP solutions for the one billion people worldwide who suffer from obstructive sleep apnea.”

Earlier in August, the company also announced significant progress on strategic programs. ProSomnus successfully received FDA registration of the company’s HWO2 buccal mucosal wellness oximeter. The ProSomnus HWO2 Device enables patients to monitor their nightly health and wellness during sleep. Specifically, users can monitor their blood oxygen saturation, pulse rate, and overall use time.

“The HWO2 Device makes it easy, comfortable, and economical to monitor nightly health and wellness. The user simply wears the device, as one might wear a retainer or orthodontic aligner. Upon removal, the device transfers the nightly data to the user’s smartphone app, where the patient can monitor and visualize their nightly health and sleep,” commented Edward T. Sall, a dentist and board-certified sleep medicine physician.

The HWO2 announcement came shortly after it introduced ProSomnus EVO Guided, the only device bioengineered to dilate the velopharynx and the oropharynx. Unlike traditional oral devices that are built around prefabricated items, each EVO Guided device is custom-fabricated directly from the prescribing provider’s digital records—without prefabricated elements or alterations to the original prescription. This enables EVO Guided to offer more room for the tongue to stay forward; a novel titration mechanism to stabilize the mandible and prevent jaw drop; and an optimized, minimalistic, anatomical design to minimize tooth separation, facilitate mouth closure, and encourage nasal breathing. The company’s post-market surveillance data indicates high levels of patient and provider satisfaction.

In acknowledgement of the growing importance of personal health information in the field of sleep medicine, ProSomnus has also announced its certification under the EU-U.S. Data Privacy Framework (DPF), the UK Extension to the EU-U.S. DPF, and the Swiss-U.S. DPF, enabling compliant cross-border transfers of personal data from Europe to the United States. ProSomnus is the first major sleep medicine company to achieve DPF certification.

The Hacienda location, which serves an estimated 107 employees, is the global headquarters for ProSomnus. The company also has locations in Germany to support its business in Europe. In 2023, ProSomnus moved its global headquarters within Hacienda, in part to keep the benefits of its central location.

For more information about ProSomnus Sleep Technologies, please visit www.prosomnus.com.